Combined Proteomic-Molecular Epidemiology Approach to Identify Precision Targets in Brain Cancer

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift


Primary brain tumors are predominantly malignant gliomas. Grade IV astrocytomas (glioblastomas, GBM) are among the most deadly of all tumors; most patients will succumb to their disease within 2 years of diagnosis despite standard of care. The grim outlook for brain tumor patients indicates that novel precision therapeutic targets must be identified. Our hypothesis is that the cancer proteomes of glioma tumors may contain protein variants that are linked to the aggressive pathology of the disease. To this end, we devised a novel workflow that combined variant proteomics with molecular epidemiological mining of public cancer data sets to identify 10 previously unrecognized variants linked to the risk of death in low grade glioma or GBM. We hypothesize that a subset of the protein variants may be successfully developed in the future as novel targets for malignant gliomas.


  • Ekaterina Mostovenko
  • Yanhong Liu
  • E. Susan Amirian
  • Spiridon Tsavachidis
  • Georgina N. Armstrong
  • Melissa L. Bondy
  • Carol L. Nilsson
Enheter & grupper
Externa organisationer
  • Virginia Commonwealth University
  • Baylor College of Medicine

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Cancer och onkologi
  • Läkemedelskemi


Sidor (från-till)80-84
Antal sidor5
TidskriftACS Chemical Neuroscience
StatusPublished - 2018 jan 17
Peer review utfördJa